GYRE
Gyre Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GYRE
Gyre Therapeutics, Inc.
A biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for the treatment of organ fibrosis
12730 High Bluff Drive, Suite 150, San Diego, CA 92130
--
Gyre Therapeutics, Inc., is incorporated in Delaware. The Company and its subsidiaries are a biopharmaceutical company dedicated to the research, development, manufacture and commercialization of innovative medicines for the treatment of organ fibrosis.
Company Financials
EPS
GYRE has released its 2025 Q3 earnings. EPS was reported at 0.03, versus the expected -0.02, beating expectations. The chart below visualizes how GYRE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GYRE has released its 2025 Q3 earnings report, with revenue of 30.56M, reflecting a YoY change of 19.92%, and net profit of 5.94M, showing a YoY change of 107.84%. The Sankey diagram below clearly presents GYRE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
